Evidence map›Paper›PMID 41204320›Full record

ArticleTrials2025

Hydrogen's Feasibility and Safety as a Therapy in Extracorporeal Cardiopulmonary Resuscitation (Hydrogen-FAST): study protocol for a trial of inhaled hydrogen gas as an adjunctive therapy in refractory cardiac arrest.

Victoria Habet, Tysen DeWaard, Krislyn M Boggs, Alix Fetch, Bao Nguyen Puente, Lynn A Sleeper, John N Kheir

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05574296 (Hydrogen's Feasibility and Safety as a Therapy in Extracorporeal Cardiopulmonary Resuscitation), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05574296 phase1recruitingnot on this map

Hydrogen's Feasibility and Safety as a Therapy in Extracorporeal Cardiopulmonary Resuscitation

TypeinterventionalSponsorBoston Children's HospitalRan2024 to 2027Enrolled53ConditionsCardiac Arrest, Extracorporeal Membrane Oxygenation, Reperfusion InjuryArmsHydrogen, Usual care
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Victoria Habet *Department of Cardiology, Division of Cardiovascular Critical Care, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA, 02115, USA.
Tysen DeWaard *Department of Cardiology, Division of Cardiovascular Critical Care, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA, 02115, USA.
Krislyn M Boggs *Department of Cardiology, Division of Cardiovascular Critical Care, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA, 02115, USA.
Alix FetchDivision of Cardiac Critical Care, Children's National Health System, Washington, DC, USA.
Bao Nguyen PuenteDivision of Cardiac Critical Care, Children's National Health System, Washington, DC, USA.
Lynn A SleeperDepartment of Cardiology, Division of Cardiovascular Critical Care, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA, 02115, USA. lynn.sleeper@childrens.harvard.edu.
John N KheirDepartment of Cardiology, Division of Cardiovascular Critical Care, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA, 02115, USA. john.kheir@childrens.harvard.edu.ORCID http://orcid.org/0000-0001-6080-8739

Funding

Multi-center, randomized, controlled trial of the feasibility and safety of inhaled hydrogen gas during ECPRR33HL164373 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI KHEIR, JOHN NAGI, SLEEPER, LYNN A · 2023 to 2025
$2.4M
Multi-center, randomized, controlled trial of the feasibility and safety of inhaled hydrogen gas during ECPRR61HL164373 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI KHEIR, JOHN NAGI, SLEEPER, LYNN A · 2022 to 2022
$411k
National Institute of Child Health and Human Development 1R61HL164373-01National Institute of Child Health and Human Development 5R33HL164373-03NHLBI NIH HHS R33 HL164373NHLBI NIH HHS R61 HL164373
6 · The paper itself

Abstract

backgroundExtracorporeal cardiopulmonary resuscitation (ECPR) improves survival for patients experiencing refractory cardiac arrest but is often associated with severe ischemia-reperfusion injury (IRI). Hydrogen gas (H

methodsThis phase 1 multicenter randomized controlled trial enrolls patients of any age undergoing ECPR due to refractory cardiac arrest associated with underlying cardiac morbidity. Due to the emergent nature of ECPR events, the trial leverages an Exception from Informed Consent enrollment process. Fifty-three participants will be randomized to standard care or standard care plus inhaled 2% H DISCUSSION: The Hydrogen-FAST trial will provide essential data on the feasibility and safety of H

trial registrationClinicalTrials.gov NCT05574296. Registered on October 6, 2022. https://clinicaltrials.gov/study/NCT05574296 .

Indexed as

Cardiopulmonary ResuscitationExtracorporeal Membrane OxygenationHeart ArrestHeart Defects, CongenitalHydrogenAdministration, InhalationAdultClinical Trials, Phase I as TopicFeasibility StudiesFemaleHumansMaleMulticenter Studies as TopicRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeHydrogenCongenital heart diseaseExtracorporeal cardiopulmonary resuscitationFeasibility studyHydrogen gasIschemia-reperfusion injuryRandomized controlled trial

Identifiers

PMID41204320
PMCPMC12595779

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.